Samsara BioCapital

Samsara BioCapital LLC is a private equity firm established in 2016 and located in Palo Alto, California. The firm specializes in investing in biotechnology companies across the United States, providing capital and strategic support to help advance innovations in the life sciences sector. Samsara BioCapital aims to identify and cultivate promising biotechnological advancements that can transform healthcare and improve patient outcomes.

Srini Akkaraju

Founder and Managing Partner

Abe Bassan

Principal

Michael Dybbs Ph.D

Partner

Cory Freedland

Partner

Past deals in Life Science

Alamar Biosciences

Series B in 2021
Alamar Biosciences develops technologies for the detection and treatment of cancer and other diseases at the earliest possible time. The company was founded in 2018 and is headquartered in Hayward, California.

Flame Biosciences

Venture Round in 2020
Flame Biosciences, Inc operates as a clinical stage company that engages in the research, development, and commercialization of transformative therapies for cancer and other inflammatory conditions. It offers FL-101 therapy for the treatment of lung cancers that are driven by inflammation; and FL-201 for reducing the chronic inflammation in patients. The company was incorporated in 2017 and is based in New York, New York.

Recursion Pharmaceuticals

Series D in 2020
Recursion Pharmaceuticals is a biotechnology company based in Salt Lake City. Recursion combines experimental biology, automation, and artificial intelligence in a massively parallel system to quickly and efficiently identify treatments for any disease which can be modeled at the cellular level. From its initial and continued focus on drug repurposing to treat rare diseases, Recursion has broadened its platform to probe rich data from high-throughput automated screens for a number of indications, including aging, inflammation, infectious disease, and immunology. Recursion is aggressively leveraging technology to build a robust and reliable map of human cellular biology, which will enable a radical shift in the pace and scale at which new treatments will benefit patients.

Fluent BioSciences

Series A in 2020
Fluent BioSciences is a privately funded life science company focused on developing high-sensitivity molecular analytical products. Utilizing proprietary instrument-free micro-self-assembly technology, the company enables the analysis of extremely low molecular and cellular sample inputs. Its platform facilitates the instantaneous self-assembly of individual cells or molecules into millions of uniform partitions, allowing for sensitive and unbiased preparation of proteins and nucleic acids for sequencing applications. This innovative approach provides researchers in the biotechnology sector with enhanced capabilities for single-cell analysis, broadening their access to advanced analytical techniques.